A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment

Thrombosis and Haemostasis

Volumn 111, Issue 1, 2013, Pages 94-102

  Turpie, Alexander G G ^a   Haas, Sylvia ^b   Kreutz, Reinhold ^c   Mantovani, Lorenzo G ^d   Pattanayak, Cassandra W ^e   Holberg, Gerlind ^f   Jamal, Waheed ^f   Schmidt, André ^f   van Eickels, Martin ^f   Lassen, Michael R ^g  

^a Department of Medicine Hamilton Health Sciences ^*  (Canada)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e HARVARD UNIVERSITY   (United States)

^f BAYER PHARMA AG   (Germany)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Bleeding events; Orthopaedic surgery; Rivaroxaban; Symptomatic thromboembolic events; Thromboprophylaxis

Indexed keywords

DABIGATRAN ETEXILATE; FONDAPARINUX; RIVAROXABAN;

ARTICLE; BLEEDING; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG SAFETY; HEALTH CARE UTILIZATION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; LIVER DISEASE; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA; THROMBOEMBOLISM; TOTAL KNEE REPLACEMENT;

BLEEDING EVENTS; ORTHOPAEDIC SURGERY; RIVAROXABAN; SYMPTOMATIC THROMBOEMBOLIC EVENTS; THROMBOPROPHYLAXIS;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; ENOXAPARIN; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; ODDS RATIO; PROPENSITY SCORE; RISK; STANDARD OF CARE; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84891851890     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-08-0666     Document Type: Article

References (15)

1. Warwick D, Friedman RJ, Agnelli G, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 2007; 89: 799-807.
2. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
3. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
4. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
5. Turpie AGG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-1680.
6. Rubin DB. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med 2007; 26: 20-36.
7. Turpie AGG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105: 444-453.
8. European Medicines Agency. Guideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk surgery. Available at: http://www.ema.europa.eu/docs/ en_GB/document_library/Scientific_guideline/2012/05/WC500127902.pdf. Accessed October 25, 2013.
9. Turpie AGG, Schmidt AC, Kreutz R, et al. Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery. Vasc Health Risk Manag 2012; 8: 363-370.
10. Holland PW. Statistics and causal inference. J Am Statistical Assoc 1986; 81: 945-960.
11. Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. J Educ Psychol 1974; 66: 668-701.
12. Rubin DB. Bayesian inference for causal effects: The role of randomization. Annals of Statistics 1978; 6: 34-58.
13. Schulman S, Angeras U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8: 202-204.
14. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Advances in Inflammatory Research. Raven Press 1984: 1-7.
15. Turpie AGG, Kreutz R, Llau J, et al. Management consensus guidance for the use of rivaroxaban-an oral, direct Factor Xa inhibitor. Thromb Haemost 2012; 108: 876-886.